Listed clinical trials firm Venn Life Sciences reported an earnings loss – before exceptional items – of €1.43m in the 12 months to 31 December 2018. Listed clinical trials firm Venn Life Sciences reported an earnings loss – before exceptional items – of €1.43m in the 12 months to 31 December 2018. Cathal Friel, CEO of Venn, described 2018 as “challenging” for the company. Loss for the year after tax was €4.8m, while the group had cash and cash equivalents of €1.1m at year-end. Shareholders are expected to vote to approve the Venn's takeover in June, as well as a name change to Open Orphan PLC.

Source: Irish Independent June 11, 2019 06:22 UTC